85 search results for: mechanism of disease
Key Pathophysiological Mechanisms of Chronic Spontaneous Urticaria Are Driven by Type 2 Inflammation
Join Dr. Jason Hawkes as he explains the importance of type 2 inflammation in chronic spontaneous urticaria.
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
This 2-hour educational program delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, and chronic spontaneous urticaria. It will highlight both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies. Experts will guide the audience through diverse patient cases to illuminate diagnostic nuances and the pathophysiology of each condition. These cases will also highlight the importance of shared decision-making and the broadening of treatment goals beyond symptom control. Dynamic panel discussion and active audience participation will be facilitated through real-time polling and curated Q&A sessions.
Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares highlights how patients with type 2 inflammatory diseases often experience multimorbidities, with overlapping symptoms that amplify their overall disease burden and impact quality of life.
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.
Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares reviews the cellular and molecular pathways underlying atopic dermatitis and considers which biomarkers may one day serve as robust measures of disease modification, despite no validated options currently being available.
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases
Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.
ADVENT On Air | Exploring PN as a Distinct and Unique Disease
Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.
ERS 2024 | What Do We Know About IL-33 Genetics?
Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis
This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.
